NFKB1 and Huntington disease: 2002; Yang et al. 2004; Brück and Wegner 2011; Schulze‐Topphoff et al. 2012). The exact mechanism for this remains unclear, although in astrocytes the down‐regulation has been shown to be a result of reduced NFκB activation (Brück et al. 2012). In HD myeloid cells, the enhanced release of proinflammatory factors is at least in part because of elevated NFκB activation (Träger et al. 2014), so investigations were made into a role of the NFκB pathway in the observed overall dampening of cytokine release from stimulated HD monocytes pre‐treated with laquinimod.